TP-PA, or Tissue Plasminogen Activator, is a medication used to dissolve blood clots in conditions like ischemic stroke and myocardial infarction. It works by converting plasminogen to plasmin, which breaks down fibrin, the main component of blood clots. Administering TP-PA quickly after the onset of symptoms can significantly improve patient outcomes. This treatment is typically given intravenously in a hospital setting. However, it is crucial to assess patients carefully, as TP-PA can increase the risk of bleeding, particularly in those with certain medical conditions or recent surgeries. Proper timing and patient selection are essential for its effectiveness.